IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v40y2022i1d10.1007_s40273-021-01077-8.html
   My bibliography  Save this article

An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia

Author

Listed:
  • Marjanne A. Piena

    (OPEN Health)

  • Natalie Houwing

    (OPEN Health)

  • Carla W. Kraan

    (OPEN Health)

  • Xiaofeng Wang

    (Otsuka Pharmaceutical Companies)

  • Heidi Waters

    (Otsuka Pharmaceutical Companies)

  • Ruth A. Duffy

    (Otsuka Pharmaceutical Companies)

  • Suresh Mallikaarjun

    (Otsuka Pharmaceutical Companies
    Virginia Commonwealth University)

  • Craig Bennison

    (OPEN Health)

Abstract

Introduction Schizophrenia is a chronic mental disorder that worsens with each relapse. Long-acting injectable (LAI) antipsychotics may prevent the exacerbation of symptoms and occurrence of relapses through improved continuity of care. Different dose regimens are available for the LAIs aripiprazole monohydrate (AM) and aripiprazole lauroxil (AL), but their cost effectiveness is unclear. Objectives The study aim was to compare costs and effects (relapses) of the different aripiprazole LAI dose regimens to inform clinical and US payer decisions. Methods A state-transition model calculated the outcomes of eight LAI dose regimens based on their relapse rates. As effectiveness data from randomized controlled trials were unavailable, relapse rates were modeled using pharmacokinetic and pharmacodynamic evidence. These described blood plasma levels of aripiprazole as a function of AM and AL dose regimens and described the probability of relapse as a function of aripiprazole blood plasma levels. The analysis had a time horizon of 1 year and took the US healthcare payer perspective. The incremental cost per relapse avoided and the probability of cost effectiveness were calculated in deterministic and probabilistic analyses. Scenario analyses explored the model’s main assumptions, and results were validated against external data and other cost-effectiveness analyses. Results Monthly administration of AM 400 mg consistently yielded the lowest predicted number of relapses across deterministic, probabilistic, and scenario analyses. The costs of treatment and relapses were projected to be the lowest with a monthly administration of AL 441 mg. The incremental cost per relapse avoided with AM 400 mg ranged from AM 400 mg being dominant to $US83,300. From willingness-to-pay thresholds of $US30,000 per relapse avoided, the probability of cost effectiveness was highest for AM 400 mg. The validation showed alignment with external data. Conclusion The analysis highlighted the robustness of the novel framework based on pharmacokinetic and pharmacodynamic evidence and demonstrated an application in a postmarketing setting.

Suggested Citation

  • Marjanne A. Piena & Natalie Houwing & Carla W. Kraan & Xiaofeng Wang & Heidi Waters & Ruth A. Duffy & Suresh Mallikaarjun & Craig Bennison, 2022. "An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia," PharmacoEconomics, Springer, vol. 40(1), pages 121-131, January.
    • Handle: RePEc:spr:pharme:v:40:y:2022:i:1:d:10.1007_s40273-021-01077-8
    DOI: 10.1007/s40273-021-01077-8
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-021-01077-8
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-021-01077-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Meenakshi Srinivasan & Annesha White & Ayyappa Chaturvedula & Valvanera Vozmediano & Stephan Schmidt & Leo Plouffe & La’Marcus T. Wingate, 2020. "Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug Development," PharmacoEconomics, Springer, vol. 38(10), pages 1031-1042, October.
    2. Andrew H. Briggs & Milton C. Weinstein & Elisabeth A. L. Fenwick & Jonathan Karnon & Mark J. Sculpher & A. David Paltiel, 2012. "Model Parameter Estimation and Uncertainty Analysis," Medical Decision Making, , vol. 32(5), pages 722-732, September.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Ezbakhe, Fatine & Pérez-Foguet, Agustí, 2021. "Decision analysis for sustainable development: The case of renewable energy planning under uncertainty," European Journal of Operational Research, Elsevier, vol. 291(2), pages 601-613.
    2. Samir S Soneji & Hai-Yen Sung & Brian A Primack & John P Pierce & James D Sargent, 2018. "Quantifying population-level health benefits and harms of e-cigarette use in the United States," PLOS ONE, Public Library of Science, vol. 13(3), pages 1-19, March.
    3. Elisa Sicuri & Silke Fernandes & Eusebio Macete & Raquel González & Ghyslain Mombo-Ngoma & Achille Massougbodgi & Salim Abdulla & August Kuwawenaruwa & Abraham Katana & Meghna Desai & Michel Cot & Mic, 2015. "Economic Evaluation of an Alternative Drug to Sulfadoxine-Pyrimethamine as Intermittent Preventive Treatment of Malaria in Pregnancy," PLOS ONE, Public Library of Science, vol. 10(4), pages 1-23, April.
    4. Naveed Chehrazi & Lauren E. Cipriano & Eva A. Enns, 2019. "Dynamics of Drug Resistance: Optimal Control of an Infectious Disease," Operations Research, INFORMS, vol. 67(3), pages 619-650, May.
    5. Jennifer A Gilbert & Sheela V Shenoi & Anthony P Moll & Gerald H Friedland & A David Paltiel & Alison P Galvani, 2016. "Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa," PLOS ONE, Public Library of Science, vol. 11(12), pages 1-19, December.
    6. Johanna Leväsluoto & Johanna Kohl & Anton Sigfrids & Jussi Pihlajamäki & Janne Martikainen, 2021. "Digitalization as an Engine for Change? Building a Vision Pathway towards a Sustainable Health Care System by Using the MLP and Health Economic Decision Modelling," Sustainability, MDPI, vol. 13(23), pages 1-24, November.
    7. Jonathan D. Campbell & R. Brett McQueen & Anne M. Libby & D. Eldon Spackman & Joshua J. Carlson & Andrew Briggs, 2015. "Cost-Effectiveness Uncertainty Analysis Methods," Medical Decision Making, , vol. 35(5), pages 596-607, July.
    8. Bromley, Hannah L. & Petrie, Dennis & Mann, G.Bruce & Nickson, Carolyn & Rea, Daniel & Roberts, Tracy E., 2019. "Valuing the health states associated with breast cancer screening programmes: A systematic review of economic measures," Social Science & Medicine, Elsevier, vol. 228(C), pages 142-154.
    9. David Epstein & Leticia García-Mochón & Stephen Kaptoge & Simon G. Thompson, 2016. "Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1041-1053, November.
    10. James Love-Koh & Susan Griffin & Edward Kataika & Paul Revill & Sibusiso Sibandze & Simon Walker & Jessica Ochalek & Mark Sculpher & Matthias Arnold, 2019. "Economic analysis for health benefits package design," Working Papers 165cherp, Centre for Health Economics, University of York.
    11. Vojtěch Kamenský & Vladimír Rogalewicz & Ondřej Gajdoš & Gleb Donin, 2022. "Discrete Event Simulation Model for Cost-Effectiveness Evaluation of Screening for Asymptomatic Patients with Lower Extremity Arterial Disease," IJERPH, MDPI, vol. 19(18), pages 1-16, September.
    12. Jeewon Park & SeungJin Bae, 2020. "Modeling Healthcare Costs Attributable to Secondhand Smoke Exposure at Home among South Korean Children," IJERPH, MDPI, vol. 17(12), pages 1-12, June.
    13. Beate Jahn & Sarah Friedrich & Joachim Behnke & Joachim Engel & Ursula Garczarek & Ralf Münnich & Markus Pauly & Adalbert Wilhelm & Olaf Wolkenhauer & Markus Zwick & Uwe Siebert & Tim Friede, 2022. "On the role of data, statistics and decisions in a pandemic," AStA Advances in Statistical Analysis, Springer;German Statistical Society, vol. 106(3), pages 349-382, September.
    14. Michał Jakubczyk & Bogumił Kamiński, 2017. "Fuzzy approach to decision analysis with multiple criteria and uncertainty in health technology assessment," Annals of Operations Research, Springer, vol. 251(1), pages 301-324, April.
    15. Dimitris Bertsimas & John Silberholz & Thomas Trikalinos, 2018. "Optimal healthcare decision making under multiple mathematical models: application in prostate cancer screening," Health Care Management Science, Springer, vol. 21(1), pages 105-118, March.
    16. Ava A John-Baptiste & Wei Wu & Paula Rochon & Geoffrey M Anderson & Chaim M Bell, 2013. "A Systematic Review and Methodological Evaluation of Published Cost-Effectiveness Analyses of Aromatase Inhibitors versus Tamoxifen in Early Stage Breast Cancer," PLOS ONE, Public Library of Science, vol. 8(5), pages 1-9, May.
    17. Jing Voon Chen & Julia L. Higle & Michael Hintlian, 2018. "A systematic approach for examining the impact of calibration uncertainty in disease modeling," Computational Management Science, Springer, vol. 15(3), pages 541-561, October.
    18. Bogumił Kamiński & Michał Jakubczyk & Przemysław Szufel, 2018. "A framework for sensitivity analysis of decision trees," Central European Journal of Operations Research, Springer;Slovak Society for Operations Research;Hungarian Operational Research Society;Czech Society for Operations Research;Österr. Gesellschaft für Operations Research (ÖGOR);Slovenian Society Informatika - Section for Operational Research;Croatian Operational Research Society, vol. 26(1), pages 135-159, March.
    19. Brown, Vicki & Diomedi, Belen Zapata & Moodie, Marj & Veerman, J. Lennert & Carter, Rob, 2016. "A systematic review of economic analyses of active transport interventions that include physical activity benefits," Transport Policy, Elsevier, vol. 45(C), pages 190-208.
    20. Yazdan Yazdanpanah & Julian Perelman & Madeline A DiLorenzo & Joana Alves & Henrique Barros & Céu Mateus & João Pereira & Kamal Mansinho & Marion Robine & Ji-Eun Park & Eric L Ross & Elena Losina & Ro, 2013. "Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness," PLOS ONE, Public Library of Science, vol. 8(12), pages 1-1, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:40:y:2022:i:1:d:10.1007_s40273-021-01077-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.